首页> 美国卫生研究院文献>Oncotarget >Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade
【2h】

Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade

机译:奎纳克林通过在TRAIL-DR5复合体之间形成功能性桥并调节线粒体固有级联反应来诱导癌细胞凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Death Receptor 5 (DR5) is known to be an important anti-cancer drug target. TRAIL is a natural ligand of DR5, but its drug action is limited because of several factors. A few agonistic ligands were identified as TRAIL-DR5 axis modulators, which enhance the cellular apoptosis. Literature suggest that quinacrine (QC) acts as a DR5 agonistic ligand. However, the detailed mechanism explaining how QC interacts with TRAIL-DR5 axis has not been established. Also focused in vitro and in vivo experimental analysis to validate the hypothesis is not yet performed. In this work, extensive studies have been carried out using in silico analysis (molecular dynamics), in vitro analysis (cell based assays) and in vivo analysis (based on mice xenograft model), to delineate the mechanism of QC action in modulating the TRAIL-DR5 signaling. The MD simulations helped in identifying the important residues contributing to the formation of a QC-TRAIL-DR5 complex, which provide extra stability to it, consequently leading to the enhanced cellular apoptosis. QC caused a dose dependent increase of DR5 expression in cancer cells but not in normal breast epithelial cells, MCF-10A. QC showed a synergistic effect with TRAIL in causing cancer cell apoptosis. In DR5-KD MCF-10A-Tr (DR5 knocked down) cells, TRAIL+ QC failed to significantly increase the apoptosis but over expression of full length DR5 in DR5-silence cells induced apoptosis, further supporting DR5 as a drug target for QC. An increase in the release of reactive species (ROS and RNS) and activation of enzymes (FADD, CASPASES 3, 8, 9 and cytochrome-C) indicated the involvement of mitochondrial intrinsic pathway in TRAIL+QC mediated apoptosis. In vivo study pointed out that TRAIL+QC co-administration increases the expression of DR5 and reduce the tumor size in xenograft mice. This combined in silico, in vitro and in vivo analysis revealed that QC enhances the cellular apoptosis via the modulation of TRAIL-DR5 complexation and the mitochondrial intrinsic pathway.
机译:已知死亡受体5(DR5)是重要的抗癌药物靶标。 TRAIL是DR5的天然配体,但由于多种因素,其药物作用受到限制。一些激动剂配体被鉴定为TRAIL-DR5轴调节剂,其增强细胞凋亡。文献表明奎纳克林(QC)充当DR5激动剂配体。但是,尚未建立解释QC如何与TRAIL-DR5轴相互作用的详细机制。还重点进行了体外和体内实验分析以验证该假设尚未执行。在这项工作中,已经使用计算机模拟分析(分子动力学),体外分析(基于细胞的测定)和体内分析(基于小鼠异种移植模型)进行了广泛的研究,以描述QC在调节TRAIL中的作用机理。 -DR5信令。 MD模拟有助于鉴定有助于形成QC-TRAIL-DR5复合物的重要残基,从而为其提供额外的稳定性,从而导致增强的细胞凋亡。 QC在癌细胞中引起DR5表达的剂量依赖性增加,但在正常乳腺上皮细胞MCF-10A中却没有。 QC显示与TRAIL协同作用导致癌细胞凋亡。在DR5-KD MCF-10A-Tr(敲低DR5)细胞中,TRAIL + QC无法显着增加细胞凋亡,但DR5-沉默细胞中全长DR5的过度表达诱导细胞凋亡,进一步支持DR5作为QC的药物靶标。反应性物种(ROS和RNS)的释放和酶(FADD,CASPASES 3、8、9和细胞色素C)的激活的增加表明线粒体内在途径参与TRAIL + QC介导的细胞凋亡。体内研究指出,TRAIL + QC共同给药可增加异种移植小鼠中DR5的表达并减小肿瘤大小。结合计算机,体外和体内分析,结果表明,QC通过调节TRAIL-DR5复合物和线粒体内在途径来增强细胞凋亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号